589228 Disclosed is the use of the combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in a ratio of from between 5:1 to 1:5 (THC:CBD) in the manufacture of a medicament for the treatment of a brain tumour, wherein the cannabinoid content is in the range of between 5 and 100mg of the total cannabinoids present, and wherein the THC and CBD may be present as plant extracts, as pure compounds, or a combination of the two.